Furiex Pharmaceuticals, Inc., a drug development collaboration company, engages in the compound partnering business in the United States and Europe. It collaborates with pharmaceutical and biotechnology companies to increase the value of their early stage drug candidates. The company has rights for compounds in various stages of development and commercialization, including rights to royalties and sales-based milestones from the collaboration with ALZA Corporation on Prilig for premature ejaculation; from Takeda Pharmaceutical Company Limited on alogliptin and alogliptin-containing products; and licenses from Janssen Pharmaceutica, N.V. for fluoroquinolone antibiotic compound for the treatment of skin and skin structure infections, such as abscesses that occur deep in the skin layers and respiratory infections, and for a compound that is a mu opioid receptor agonist and delta opioid receptor antagonist. Its collaborations also comprise license from Ranbaxy Laboratories, Ltd. for statin compound for the treatment of dyslipidemia; and for various therapeutic candidates developed by Eli Lilly and Company. The company was founded in 1998 and is headquartered in Morrisville, North Carolina. Furiex Pharmaceuticals, Inc. (NasdaqGM:FURX) operates independently of Pharmaceutical Product Development Inc. as of June 15, 2010.